2009 Is ImmunoGen’s Make-Or-Break Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The antibody-drug conjugate company has struggled for validation while supporting itself with partner funds, but a spate of data due this year could spark a turnaround.
You may also be interested in...
ImmunoGen Gains Momentum On Success Of T-DM1, The Herceptin Conjugate In Development By Roche/Genentech
Buoyed by the affirmation of its conjugation technology brought by the imminent filing of T-DM1, ImmunoGen is focused on building an internal pipeline with future emphasis co-development deals, not just outlicensing.
ImmunoGen Gains Momentum On Success Of T-DM1, The Herceptin Conjugate In Development By Roche/Genentech
Buoyed by the affirmation of its conjugation technology brought by the imminent filing of T-DM1, ImmunoGen is focused on building an internal pipeline with future emphasis co-development deals, not just outlicensing.
For ImmunoGen, A Lot Depends On Herceptin-Based Conjugate T-DM1
Eight compounds currently in the clinic rely on ImmunoGen's technology for creating antibody-cytotoxin linked cancer drugs, with another two to four expected to reach that stage in 2010